Last week, at the NDP Convention, the delegates insisted that the Liberals deliver a pharmacare program by 2025 or their deal was off. Susan Delacourt writes:
Their arrangement clearly states that a “Canada pharmacare act” must be passed by the end of 2023, and that deadline is looming ever closer with no sign of legislation on the horizon.
“We have now the leverage given to us by our convention and our members,” Singh told reporters this week, using a bit of megaphone diplomacy to warn of tense negotiations to come with the Liberals.
Don Davies, the NDP health critic, is also ramping up the public pressure on Trudeau’s Liberals, calling pharmacare the “red line” that could spell the end of the supply and confidence agreement.
The gurus in the Finance Department -- who have Chrystia Freeland's ear -- are warning that the present economy can't support pharmacare:
Behind closed doors at the cabinet and caucus retreats in August and September, Freeland essentially warned her colleagues that while Liberals will continue to be Liberals, investing in existing large spending programs, this government can’t do everything. Here’s how she put it when talking to reporters last month:
“We are Liberals. We believe government has an important role to play in supporting Canadians, in building a social welfare net that supports Canadians and in putting in place programs that help our economy to grow.”
There was a “but” there, though. “We also understand that government is able to deliver for Canadians when government operates on a responsible fiscal footing and that, by the way, is a profoundly Liberal conviction. It was Jean Chrétien and Paul Martin that did the very hard work of fighting to get the triple-A (credit) rating that Canada currently enjoys. And what we are committed to is doing the things Canadians need us to do and maintaining that responsible fiscal foundation, and we are doing that. Canada has a triple-A rating, notwithstanding the great investments we’ve made in Canadians.”
Freeland and her Finance Department officials are said to be worried that a new pharmacare program would affect those credit ratings. It didn’t help either that the Parliamentary Budget Officer came out with a report last week, putting the cost of national pharmacare at $11.2 billion in the first year and $13.4 billion in five years.
You can bet that Singh and Trudeau are trying to find a way to finesse the deal.
Image: The Council Of Canadians

